Neurocrine's Vykat XR Linked to Patient Deaths and Serious Adverse Events in Prader-Willi Syndrome
核心洞察
A group of Prader-Willi syndrome (搜索) physicians and experts notified clinicians of patient deaths and severe side effects potentially associated with Vykat XR (搜索), a newly approved Neurocrine Biosciences drug.
Seven people prescribed Vykat XR (搜索) have died since its FDA approval in March 2025, according to the FDA's Adverse Event Monitoring System.
More than 100 reports of serious adverse events, mostly hospitalizations for swelling, respiratory, and heart complications, have been reported to the FDA.
A group of physicians and experts in Prader-Willi syndrome (搜索) (PWS), a rare disease that causes an insatiable desire to eat, on Tuesday notified clinicians of a series of patient deaths and cases of severe side effects potentially associated with Vykat XR (搜索), a newly approved drug sold by Neurocrine Biosciences.
Vykat was approved by the Food and Drug Administration in March 2025 to curb the intense hunger sensation in children and adults with Prader-Willi syndrome (搜索). But since its clearance, seven people prescribed the drug have died, according to the FDA's Adverse Event Monitoring System. Additionally, more than 100 reports of serious adverse events, mostly cases of patients being hospitalized for swelling, respiratory, and heart complications, have been reported to the FDA.
The notification from physicians and experts in the field marks a significant development for a drug that was cleared less than two years ago, raising questions about the post-marketing safety profile of Vykat XR (搜索) in a patient population with complex medical needs.